New developments in clinical immunosuppression.
Over the last few years, the armamentarium of immunosuppressants has been enriched by a variety of new drugs, that have helped to further reduce the incidence of acute rejection episodes after kidney transplantation. Nevertheless the search for new compounds drugs continues, until tolerance, the ultimate goal of transplantation medicine can be achieved. Meanwhile we should appreciate that neither all drugs nor all patients are equal and tailor the immunosuppression to the patients' needs. To define patient groups who benefit most from different immunosuppressive protocols especially in regard to long term allograft and patient survival will warrant further prospective controlled trials.
Watschinger
B
B
Department of Internal Medicine III Renal Division, University of Vienna, Austria.
Wenter
C
C
Demetriou
D
D
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2